Earlier genetic testing in men with very low sperm counts may spare unnecessary testing or surgery, according to Ronald Anglade, MD.
Opinion|Podcasts|January 14, 2025
Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges
Author(s)Wayne Kuang, MD, Steven Maislos, MD
Listen
0:00 / 0:00
Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.
Advertisement
54:53-58:54 OAB Comobidities
58:49-1:06:13 OAB Care
1:06:14-1:10:48 Innovations in OAB Management
1:10:49-1:14:08 Shared Decision-Making in OAB
1:14:09-1:21:40 Implications of Untreated OAB
1:21:41-1:29:44 OAB Treatment Medical Landscape
Advertisement
Related to this article
Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.
A national survey of US military service members and veterans with NMIBC found that more than half were diagnosed by age 50, while 63% reported treatment access barriers.
VOLGA results raise the question of treatment de-intensification in perioperative MIBC care, according to Suzanne B. Merrill, MD, FACS.
Virtuoso Surgical expects to initiate a focused US launch at leading urology centers in 2027.
Pasritamig is being evaluated with or without JNJ-9401 in the ongoing phase 3 KLK2-comPAS trial.
The combination of nogapendekin alfa inbakicept plus BCG demonstrated a statistically significant improvement in efficacy vs BCG alone.
These FAQs outline key recommendations from ASTRO's updated guideline on shorter-course radiation therapy for localized prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection
2
Survey: Service members and veterans with NMIBC report barriers to treatment access
3
BCG-naïve NMIBC: Optimizing initial treatment selection
4
Q&A: Ronald Anglade, MD, on genetic testing in male infertility
5